Literature DB >> 20820945

Disseminated carcinoma diagnosed by bone marrow biopsy in patients with microangiopathic hemolytic anemia and thrombocytopenia: a report of two cases with gastric cancer and a review of the literature.

Orit Kaidar-Person1, Haitam Nasrallah, Nissim Haim, Eldad J Dann, Gil Bar-Sela.   

Abstract

INTRODUCTION: Malignancy is often associated with hematological disorders, but rarely is the diagnosis of malignancy secondary to the diagnosis of microangiopathic hemolytic anemia and thrombocytopenia. CASE REPORTS: We report hereby two patients with metastatic gastric carcinoma presenting with microangiopathic hemolytic anemia and thrombocytopenia. Despite chemotherapy and repeated plasmapheresis in one patient, both patients succumbed shortly after the diagnosis of cancer was made.
CONCLUSION: A review of the literature regarding microangiopathic hemolytic anemia in cancer patients is discussed. In patients suffering from microangiopathic hemolytic anemia and thrombocytopenia, malignancy should be considered as a possible cause. Early diagnosis of malignancy may be critical for determining the patient's prognosis and potentially avoiding unnecessary overtreatment.

Entities:  

Mesh:

Year:  2011        PMID: 20820945     DOI: 10.1007/s12029-010-9204-6

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  29 in total

1.  Thrombotic thrombocytopenic purpura secondary to an occult adenocarcinoma.

Authors:  Maria Teresa Pirrotta; Alessandro Bucalossi; Francesco Forconi; Monica Bocchia; Serena Mazzotta; Simona Sammassimo; Alessandro Gozzetti; Francesco Lauria
Journal:  Oncologist       Date:  2005-04

2.  Purpura in a patient with disseminated breast cancer: a rapidly progressive cancer-related thrombotic thrombocytopenic purpura.

Authors:  I Spoormans; S Altintas; J Van den Brande; A Luijks; J B Vermorken
Journal:  Ann Oncol       Date:  2008-04-11       Impact factor: 32.976

3.  Survival and relapse in patients with thrombotic thrombocytopenic purpura.

Authors:  Johanna A Kremer Hovinga; Sara K Vesely; Deirdra R Terrell; Bernhard Lämmle; James N George
Journal:  Blood       Date:  2009-12-23       Impact factor: 22.113

4.  Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.

Authors:  P N Lara; T L Coe; H Zhou; L Fernando; P V Holland; T Wun
Journal:  Am J Med       Date:  1999-12       Impact factor: 4.965

5.  Hemolytic uremic syndrome and prostatic adenocarcinoma.

Authors:  M Eugene; G Deray; P Cacoub; A Achour; A Baumelou
Journal:  Clin Nephrol       Date:  1987-01       Impact factor: 0.975

Review 6.  Thrombotic microangiopathy in the cancer patient including those induced by chemotherapeutic agents.

Authors:  A J Murgo
Journal:  Semin Hematol       Date:  1987-07       Impact factor: 3.851

7.  Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.

Authors:  G A Rock; K H Shumak; N A Buskard; V S Blanchette; J G Kelton; R C Nair; R A Spasoff
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

8.  Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients.

Authors:  W R Bell; H G Braine; P M Ness; T S Kickler
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

9.  Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura.

Authors:  M Furlan; R Robles; M Solenthaler; B Lämmle
Journal:  Blood       Date:  1998-04-15       Impact factor: 22.113

10.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.

Authors:  G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

View more
  6 in total

1.  The role of chemotherapy in gastric cancer-related microangiopathic haemolytic anaemia.

Authors:  Monica Tang; David Goldstein
Journal:  J Gastrointest Oncol       Date:  2017-02

2.  Cancer risk of petrochemical workers exposed to airborne PAHs in industrial Lanzhou City, China.

Authors:  Li Wang; Yuan Zhao; Xianying Liu; Tao Huang; Yanan Wang; Hong Gao; Jianmin Ma
Journal:  Environ Sci Pollut Res Int       Date:  2015-08-19       Impact factor: 4.223

Review 3.  Microangiopathic hemolytic anemia as the first manifestation of metastatic signet ring cell carcinoma of unknown origin: a case report and review of literature.

Authors:  Sang-Yong Shin; Hyosoon Park; Seoung Wan Chae; Hee-Yeon Woo
Journal:  Korean J Lab Med       Date:  2011-06-28

4.  Isolated hemolytic anemia: an unusual manifestation of occult malignancy.

Authors:  Matthew J Butler; Ming Yin; Fahd Quddus
Journal:  Hematol Rep       Date:  2014-02-05

5.  Cisplatin and short-term 5-Fluorouracil infusion for paraneoplastic microangiopathic hemolytic anemia in gastric cancer: a case report and review of the literature.

Authors:  M S Sanatani; A Lazo-Langner; I M Al-Rasheedy
Journal:  Case Rep Oncol Med       Date:  2013-12-29

Review 6.  How I treat microangiopathic hemolytic anemia in patients with cancer.

Authors:  M R Thomas; M Scully
Journal:  Blood       Date:  2021-03-11       Impact factor: 22.113

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.